Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia

References

• McMillan, R. 2000. The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin. Hematol. 37: 5–9
   PubMed Web of Science ®Google Scholar
• Cines, D. B., A. Cuker, and J. W. Semple. 2014. Pathogenesis of immune thrombocytopenia. Presse. Med. 43: e49–e59
   PubMedGoogle Scholar
• Olsson, B., P. O. Andersson, M. Jernas, et al. 2003. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med. 9: 1123–1124
   PubMed Web of Science ®Google Scholar
• Zhang, F., X. Chu, L. Wang, et al. 2006. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur. J. Haematol. 76: 427–431
   PubMed Web of Science ®Google Scholar
• Liu, B., H. Zhao, M. C. Poon, et al. 2007. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur. J. Haematol. 78: 139–143
   PubMed Web of Science ®Google Scholar
• McKenzie, C. G., L. Guo, J. Freedman, and J. W. Semple. 2013. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br. J. Haematol. 163: 10–23
   PubMed Web of Science ®Google Scholar
• Wang, T., H. Zhao, H. Ren, et al. 2005. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica. 90: 914–923
   PubMed Web of Science ®Google Scholar
• Ling, V. 1997. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer chemother Pharmacol. 40: S3–S8
   PubMed Web of Science ®Google Scholar
• Picchianti-Diamanti, A., M. M. Rosado, M. Scarsella, et al. 2014. P-glycoprotein and drug resistance in systemic autoimmune diseases. Int. J. Mol. Sci. 15: 4965–4976
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W., A. A. Ruefli, and M. J. Smyth. 2000. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends. Biochem. Sci. 25: 1–6
   PubMed Web of Science ®Google Scholar
• Schluesener, H. J. 1991. Transforming growth factors type beta inhibit multidrug transport in rat astrocyte cell lines. Autoimmunity. 9: 269–275
   PubMedGoogle Scholar
• Gottesman, M. M., and I. Pastan. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62: 385–427
   PubMed Web of Science ®Google Scholar
• Ford, J. M., and W. N. Hait. 1990. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42: 155–199
   PubMed Web of Science ®Google Scholar
• Tsujimura, S., K. Saito, S. Nakayamada, et al. 2005. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis. Rheum. 52: 1676–1683
   PubMed Web of Science ®Google Scholar
• Tsujimura, S., K. Saito, M. Nawata, et al. 2008. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann. Rheum. Dis. 67: 380–388
   PubMed Web of Science ®Google Scholar
• Shinoda, M., Y. Tanaka, T. Kuno, et al. 2004. High levels of autoantibodies against drug-metabolizing enzymes in SLA/LP-positive AIH-1 sera. Autoimmunity. 37: 473–480
   PubMed Web of Science ®Google Scholar
• Pendse, S. S., D. M. Briscoe, and M. H. Frank. 2003. P-glycoprotein and alloimmune T-cell activation. Clin. Appl. Immunol. Rev. 4: 3–14
   PubMedGoogle Scholar
• Drach, J., A. Gsur, G. Hamilton, et al. 1996. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood. 88: 1747–1754
   PubMed Web of Science ®Google Scholar
• Frank, M. H., M. D. Denton, S. I. Alexander, et al. 2001. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J. Immunol. 166: 2451–2459
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W., E. Cretney, and M. J. Smyth. 1999. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 93: 1075–1085
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W., A. A. Ruefli, K. M. Tainton, and M. J. Smyth. 2000. A role for P-glycoprotein in regulating cell death. Leuk. Lymphoma. 38: 1–11
   PubMed Web of Science ®Google Scholar
• Gupta, S., C. H. Kim, T. Tsuruo, and S. Gollapudi. 1992. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J. Clin. Immunol. 12: 451–458
   PubMed Web of Science ®Google Scholar
• Xuan, M., H. Li, R. Fu, et al. 2014. Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia. Hum. Immunol. 75: 317–321
   PubMed Web of Science ®Google Scholar
• Akin, M., S. Turgut, C. Ayada, et al. 2011. Relation between 3435C > T multidrug resistance 1 gene polymorphism with high dose methylprednisolone treatment of childhood acute idiopathic thrombocytopenic purpura. Gene. 487: 80–83
   PubMed Web of Science ®Google Scholar
• Levy, A. S., S. Cunningham-Rundles, B. Mazza, et al. 2002. High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br. J. Haematol. 118: 836–838
   PubMed Web of Science ®Google Scholar
• Ruiz-Soto, R., Y. Richaud-Patin, X. Lopez-Karpovitch, and L. Llorente. 2003. Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. Exp. Hematol. 31: 483–487
   PubMed Web of Science ®Google Scholar
• Lopez-Karpovitch, X., G. Graue, E. Crespo-Solis, and J. Piedras. 2008. Multidrug resistance-1 in T lymphocytes and natural killer cells of adults with idiopathic thrombocytopenic purpura: effect of prednisone treatment. Arch. Med. Res. 39: 541–545
   PubMed Web of Science ®Google Scholar
• Rodeghiero, F., R. Stasi, T. Gernsheimer, et al. 2009. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 113: 2386–2393
   PubMed Web of Science ®Google Scholar
• Neunert, C., W. Lim, M. Crowther, et al. American Society of. 2011. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 117: 4190–4207
   PubMed Web of Science ®Google Scholar
• Tsujimura, S., K. Saito, S. Nakayamada, and Y. Tanaka. 2007. Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus. Histol. Histopathol. 22: 465–468
   PubMed Web of Science ®Google Scholar
• Suzuki, K., K. Saito, S. Tsujimura, et al. 2010. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J. Rheumatol. 37: 512–520
   PubMed Web of Science ®Google Scholar
• Randolph, G. J., S. Beaulieu, M. Pope, et al. 1998. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. USA. 95: 6924–6929
   PubMed Web of Science ®Google Scholar
• Raghu, G., S. W. Park, I. B. Roninson, and E. B. Mechetner. 1996. Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp. Hematol. 24: 1258–1264
   PubMed Web of Science ®Google Scholar
• Chaudhary, P. M., and I. B. Roninson. 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66: 85–94
   PubMed Web of Science ®Google Scholar
• van der Bliek, A. M., P. M. Kooiman, C. Schneider, and P. Borst. 1988. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene. 71: 401–411
   PubMed Web of Science ®Google Scholar
• Schinkel, A. H., E. M. Roelofs, and P. Borst. 1991. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res. 51: 2628–2635
   PubMed Web of Science ®Google Scholar
• Llaudo, I., L. Cassis, J. Torras, et al. 2012. Impact of small molecules immunosuppressants on P-glycoprotein activity and T-cell function. J. Pharm. Pharm. Sci. 15: 407–419
   PubMed Web of Science ®Google Scholar
• Ramesh, R., L. Kozhaya, K. McKevitt, et al. 2014. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J. Exp. Med. 211: 89–104
   PubMed Web of Science ®Google Scholar
• Pendse, S. S., S. Behjati, T. Schatton, et al. 2006. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am. J. Transplant. 6: 2884–2893
   PubMed Web of Science ®Google Scholar
• Audia, S., M. Samson, M. Mahevas, et al. 2013. Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. Blood. 122: 2477–2486
   PubMed Web of Science ®Google Scholar
• Chow, L., R. Aslam, E. R. Speck, et al. 2010. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood. 115: 1247–1253
   PubMed Web of Science ®Google Scholar
• Li, S., L. Wang, C. Zhao, et al. 2007. CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br. J. Haematol. 139: 605–611
   PubMed Web of Science ®Google Scholar
• Ma L, E. Simpson, J. Li, et al. 2015. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia. Blood. 126: 247–256
   PubMed Web of Science ®Google Scholar
• Bruserud, O., W. Hamann, S. Patel, and G. Pawelec. 1992. CD4+ TCR alpha beta + T-cell clones derived shortly after allogeneic bone marrow transplantation: theophyllamine and verapamil inhibit proliferation of functionally heterogeneous T-cells. Int. J. Immunopharmacol. 14:783–789
   PubMed Web of Science ®Google Scholar
• Cornwell, M. M., I. Pastan, and M. M. Gottesman. 1987. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262: 2166–2170
   PubMed Web of Science ®Google Scholar
• Kim, R. B. 2002. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug. Metab. Rev. 34: 47–54
   PubMed Web of Science ®Google Scholar
• Miller, T. P., T. M. Grogan, W. S. Dalton, et al. 1991. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9: 17–24
   PubMed Web of Science ®Google Scholar
• Morjani, H., and C. Madoulet. 2010. Immunosuppressors as multidrug resistance reversal agents. Methods Mol. Biol. 596: 433–446
   PubMedGoogle Scholar
• Iwata, S., K. Saito, K. Yamaoka, et al. 2009. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology. 48: 1012–1013
   PubMed Web of Science ®Google Scholar
• Laupeze, B., L. Amiot, L. Payen, et al. 2001. Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sci. 68: 1323–1331
   PubMed Web of Science ®Google Scholar
• Moon, Y. J., S. Zhang, and M. E. Morris. 2007. Real-time quantitative polymerase chain reaction for BCRP, MDR1, and MRP1 mRNA levels in lymphocytes and monocytes. Acta Haematol. 118: 169–175
   PubMed Web of Science ®Google Scholar